HCI-033 breast cancer PDX

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

• Research area: Breast Cancer
• Description: Human breast cancer patient-derived xenograft (PDX) model that retains high fidelity to original tumour, including spatial structure, intratumour heterogeneity, genomic features, tumour growth rate, metastatic patterns, and drug responses. These highly translatable PDX models can be used to more accurately assess therapeutic efficacy and predict patient responses in preclinical drug validation studies than traditional models. This panel of PDX models includes some of the deadliest forms of breast cancer such as drug-resistant, metastatic tumours, and endocrine-resistant estrogen receptor-positive (ER+) and human epidermal growth factor receptor positive (HER2+) tumours. Sample collected from lung met of Caucasian female, age 60 at time of collection with a primary diagnosis of DCIS; 2005, breast recurrence 2015, lung mets 2017. Patient had no former history of smoking and had clinical metastasis in lung and chest wall detected. Patient had undergone radiation therapy of breast 2005-2006 and had received systemic treatment of tamoxifen 2006; dose dense doxorubicin, cyclophosphamide 2015- 2016; taxol low dose 2016; carboplatin 2016; capecitabine 2016 prior to sample collection. Patient and PDX characteristics were as follows - ER status: negative, PR status: negative, HER2 status: negative. PDX information: PAM50 subtype not done and metastasis tests not done.

Patient Details

• Cancer type: Breast Cancer
• Cancer subtype: Ductal Darcinoma in Situ, Lung metastasis
• Biopsy site: Lung metastasis
• Gender: Female
• Patient ethnicity: Caucasian
• Treatment history: Pretreated: Patient had undergone radiation therapy of breast 2005-2006 and had received systemic treatment of tamoxifen 2006; dose dense doxorubicin, cyclophosphamide 2015- 2016; taxol low dose 2016; carboplatin 2016; capecitabine 2016 prior to sample collection

Engraftment Details

• Mice passaged: Yes
• Engraftment site: Cleared mammary fat pad
• Host strain: Immunocompromised mice NOD scid gamma (NSG) Jackson Laboratory 5557; NOD/scid, Jackson Laboratory 1303 or NOD rag gamma (NRG), Jackson Laboratory 7799
• Production details: Fresh or thawed human breast tumour fragments were implanted into the cleared inguinal mammary fat pad of female Immune-compromised mice. For bone metastasis samples, bone fragments were coimplanted. For liquid specimens, pleural effusion, or ascites fluid, 1-2 milion cells were injected into cleared mammary fat pads in Matrigel. For ER+ tumours, mice were dosed with E2 beeswax pellets and given supplemental E2 via drinking water. When tumours reached 1-2 cm in diameter, tumours were aseptically collected and reimplanted into new m ice or banked. Estrogen-independent ER+ breast PDX models were generated when ER+ PDX tumours were transplated into overiectomized mice without E2 supplementation.

Handling

• Initial handling information: Implant into the cleared inguinal mammary fat pad of female Immune-compromised mice NSG and NRG. Both NSG (fresh) and NRG (fresh) time to growth: 4 months to 2 cm
• Additional notes: Additional Information on PDX establishment: https://www.nature.com/articles/s43018-022-00337-6/figures/9

References

• Tufail, et al. 2024. Journal of Translational Med. Jan 3:22(1):15. PMID: 38172946
• Bhattacharya, et al. 2023. Journal of Experimental & Clinical Cancer Research. Dec 16:42(1):343. PMID: 38102637
• Prekovic, et al. 2023. EMBO Molecular Medicine. Dec 7:15(12):e17737. PMID: 37902007
• Daneshdoust, et al. 2023. Cells. Sep 30:12(19):2338. PMID: 37830602
• Wang, et al. 2023. Cell Bioscience. Dec 1:13(1):224. PMID: 38041134
• Guillen, et al. 2022. Nature Cancer. Feb 3(2):232-250. PMID: 35221336